⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147306 | 0.71 | RHEB (0.34) | — | |
| SCHEMBL24823524 | 0.68 | HTR2A (0.37) | — | |
| SCHEMBL21725648 | 0.62 | SLC6A2 (0.37) | — | |
| SCHEMBL12565905 | 0.61 | BRD4 (0.33) | — | |
| SCHEMBL35211219 | 0.61 | HTR2A (0.33) | — | |
| SCHEMBL929611 | 0.60 | IDO1 (0.44) | — | |
| SCHEMBL21725649 | 0.59 | ALDH1A1 (0.35) | — | |
| SCHEMBL12182595 | 0.59 | TDP1 (0.34) | — | |
| SCHEMBL17970548 | 0.59 | KDM4A (0.41) | — | |
| SCHEMBL18876114 | 0.58 | RHEB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |